Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

81. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A. Denosumab versus bifosfonatos para el tratamiento de la osteoporosis

Health Technology Assessment (HTA) Database.2014

82. Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines

Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation CADTH. Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions Three non-randomized studies were identified regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis

Health Technology Assessment (HTA) Database.2014

83. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis

Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Lassemillante AC, Doi SA, Hooper JD, Prins JB, Wright OR CRD summary This review concluded that the prevalence of osteoporosis in patients with prostate cancer who were undergoing androgen deprivation therapy was high, and that variation appeared to be due to treatment duration (...) , disease stage, ethnicity, and skeletal site of diagnosis. These conclusions largely reflect the evidence presented. Methodological limitations mean that the overall reliability of the review is uncertain. Authors' objectives To evaluate the prevalence of osteoporosis in men with prostate cancer who were undergoing androgen deprivation therapy. Searching EMBASE, PubMed, and Scopus were searched to December 2012, for studies published in English. Search terms were reported. Study selection Eligible

DARE.2014

84. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C CRD summary The authors concluded that there were differences (...) in fracture risk reduction profiles between pharmacologic therapies for postmenopausal osteoporosis and the findings may assist therapy choice. The authors’ conclusions are generally suitably cautious but it remains unclear which of the treatments for osteoporosis most effective. Authors' objectives To assess the effectiveness of postmenopausal osteoporosis therapies in reducing fracture risk. Searching MEDLINE (from 1950), EMBASE (from 1980), CINAHL and Cochrane Central Register of Controlled Trials

DARE.2014

85. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis

Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis Ding H, Yang L, Du W, Teng Y, Fu SJ, Tao (...) of bisphosphonates for prevention and treatment of osteoporosis in men with non-metastatic prostate cancer receiving androgen deprivation therapy. Searching PubMed, EMBASE, The Cochrane Library, Science Citation Index, and Chinese Biomedicine Database were searched up to October 2012 with no language restrictions. Google was searched for related references. Reference lists of relevant studies were also searched and experts in the field contacted. Only published studies were sought. Study selection Randomised

DARE.2014

86. Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients ? a systematic review and meta-analysis

Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients ? a systematic review and meta-analysis Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury osteoporosis in spinal cord injury patients – a systematic review and meta-analysis Effectiveness of bisphosphonate analogues and functional electrical stimulation on attenuating post-injury (...) osteoporosis in spinal cord injury patients – a systematic review and meta-analysis Chang KV, Hung CY, Chen WS, Lai MS, Chien KL, Han DS CRD summary The authors concluded that the early administration of bisphosphonates after spinal cord injury effectively reduced sub-lesional bone loss. Functional electrical stimulation for chronic injury could significantly increase sub-lesional bone mineral density. They relied on before-and-after data, which limits the comparison of intervention effectiveness. Small

DARE.2014

87. [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program]

[Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription (...) drug insurance program] Portrait de l'usage des bisphosphonates et du denosumab chez les personnes de 50 ans ou plus souffrant d'osteoporose couvertes par le regime public d'assurance medicaments [Portrait of the use of bisphosphonates and denosumab in patients aged 50 years or older with osteoporosis who are covered by the public prescription drug insurance program] Tremblay E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

Health Technology Assessment (HTA) Database.2014

89. Sclerostin Inhibition for Osteoporosis - A New Approach.

Sclerostin Inhibition for Osteoporosis - A New Approach. Sclerostin inhibition for osteoporosis--a new approach. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 24382003 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2014 Jan 30;370(5):476-7. doi: 10.1056/NEJMe1315500. Epub 2014 Jan 1. Sclerostin inhibition for osteoporosis--a new approach. 1 . 1 From Brigham and Women's Hospital, Boston. Comment on [N Engl J Med. 2014] PMID: 24382003 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical PubMed

NEJM2014

90. PLS3 mutations in X-linked osteoporosis with fractures.

PLS3 mutations in X-linked osteoporosis with fractures. Plastin 3 (PLS3), a protein involved in the formation of filamentous actin (F-actin) bundles, appears to be important in human bone health, on the basis of pathogenic variants in PLS3 in five families with X-linked osteoporosis and osteoporotic fractures that we report here. The bone-regulatory properties of PLS3 were supported by in vivo analyses in zebrafish. Furthermore, in an additional five families (described in less detail) referred (...) for diagnosis or ruling out of osteogenesis imperfecta type I, a rare variant (rs140121121) in PLS3 was found. This variant was also associated with a risk of fracture among elderly heterozygous women that was two times as high as that among noncarriers, which indicates that genetic variation in PLS3 is a novel etiologic factor involved in common, multi-factorial osteoporosis.

NEJM2013

91. Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia

Building healthy bones throughout life. An evidence-informed strategy to prevent osteoporosis in Australia Building healthy bones throughout life: an evidence-informed strategy to prevent osteoporosis in Australia | Medical Journal of Australia Search form Search Articles Topics MJA team Author centre Multimedia Centenary Place an ad secondlevel Building healthy bones throughout life: an evidence-informed strategy to prevent osteoporosis in Australia Peter R Ebeling, Robin M Daly, Deborah (...) A Kerr and Michael G Kimlin MJA Open 2013; 2 Suppl 1: 1. doi: 10.5694/mjao12.11363 This article has been republished in the A white paper resulting from the outcomes of the Osteoporosis Australia Summit, 20 October 2011 A PDF of the précis of this white paper that was published in print can be downloaded . Contents Rationale and objectives Acronyms Acronym Term 1,25(OH) 2 D 1,25-dihydroxyvitamin D 25(OH)D 25-hydroxyvitamin D AI adequate intake ANZBMS Australian and New Zealand Bone and Mineral

Clinical Practice Guidelines Portal2013

92. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) tool aiding in the diagnosis of osteoporosis? Clinical Bottom Line Evidence shows that Eroded Appearance of the Inferior Mandibular cortex in a panoramic radiograph is an Effective Indicator for osteoporosis in postmenopausal women. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Taguchi/2004 316 women with a mean age 56.8 were recruited for this study subjects were divided into Two Groups: 159 Healthy

UTHSCSA Dental School CAT Library2013

93. Odanacatib for male osteoporosis ? first and second line

Odanacatib for male osteoporosis ? first and second line Odanacatib for male osteoporosis – first and second line Odanacatib for male osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Odanacatib for male osteoporosis – first and second line. Birmingham: NIHR Horizon Scanning Centre (...) (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biphenyl Compounds /therapeutic use; Humans; Male; Men; Osteoporosis /drug therapy Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham

Health Technology Assessment (HTA) Database.2013

94. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. BACKGROUND: Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone. METHODS: From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis

Lancet2013

96. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta.

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. This report identifies human skeletal diseases associated with mutations in WNT1. In 10 family members with dominantly inherited, early-onset osteoporosis, we identified a heterozygous missense mutation in WNT1, c.652T→G (p.Cys218Gly). In a separate family with 2 siblings affected by recessive osteogenesis imperfecta, we identified a homozygous nonsense mutation, c.884C→A, p.Ser295*. In vitro, aberrant forms of the WNT1

NEJM2013 Full Text: Link to full Text with Trip Pro

97. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications.

Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. BACKGROUND: Osteoporosis is a prevalent but underdiagnosed condition. OBJECTIVE: To evaluate computed tomography (CT)-derived bone mineral density (BMD) assessment compared with dual-energy x-ray absorptiometry (DXA) measures for identifying osteoporosis by using CT scans performed for other clinical indications. DESIGN: Cross-sectional study. SETTING: Single academic health center (...) . PATIENTS: 1867 adults undergoing CT and DXA (n = 2067 pairs) within a 6-month period over 10 years. MEASUREMENTS: CT-attenuation values (in Hounsfield units [HU]) of trabecular bone between the T12 and L5 vertebral levels, with an emphasis on L1 measures (study test); DXA BMD measures (reference standard). Sagittal CT images assessed for moderate-to-severe vertebral fractures. RESULTS: CT-attenuation values were significantly lower at all vertebral levels for patients with DXA-defined osteoporosis (P

Annals of Internal Medicine2013 Full Text: Link to full Text with Trip Pro

98. Osteoporosis - Diagnosis and Treatment

Osteoporosis - Diagnosis and Treatment BC Guidelines - Province of British Columbia Search default_collection default_frontend MENU theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Health theme_2_collection theme_2_frontend theme_2_collection theme_2_frontend Birth, Adoption, Death, Marriage & Divorce theme_4_collection theme_4_frontend theme_4_collection

Clinical Practice Guidelines and Protocols in British Columbia2013

99. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence (...) and resources for children's oral health Visit the Ad Council's children's oral health website Evidence Education About * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years

ADA Center for Evidence-Based Dentistry2013

100. Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities

Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice (...) and resources for children's oral health Visit the Ad Council's children's oral health website Evidence Education About * Associated Topics Poor quality evidence for an increased CVD prevalence, osteoporosis prevalence, and/or risk factors in women 45 years or older with disabilities Susan Parker RDH, B.S., MEd, MBA . Overview Systematic Review Conclusion The authors found poor quality evidence for an increased prevalence of cardiovascular disease (CVD) and/or its risk factors among disabled women 45 years

ADA Center for Evidence-Based Dentistry2013